

## Per-capita consumption of analgesics: a nine-country survey over 20 years

H.-C. Diener · R. Schneider · B. Aicher

Published online: 20 August 2008  
© Springer-Verlag 2008

### Erratum to: J Headache Pain DOI 10.1007/s10194-008-0046-6

This article unfortunately contained errors in two places.

1. The two columns of data in Table 1 were under the wrong headings. The correct version of Table 1 is given here:

2. Incorrect percentages were given in the last paragraph of the “Results” section, immediately before the “Discussion”. The corrected paragraph is as follows:

In 2005 in the prescription (Rx) group of N2B analgesics, combination products accounted for approx. 33% of all Rx analgesics in terms of SU. The most important combinations are tilidine plus naloxone (14% of all SU in the Rx group), followed by codeine plus paracetamol (12%). The predominating single products in the Rx group are metamizole (36%) and tramadol (21%). Growth in the Rx group can be seen for both the combinations named and the single products.

**Table 1** Relative proportions of standardised medication units (SU) among different countries comparing weighted and unweighted proportions

Relative proportions of ASA consumption	Unweighted (%)	Weighted by mg ASA (%)
USA	58.2	48.3
Germany (West)	16.0	19.7
Canada	12.2	10.7
France	9.7	16.7
Sweden	1.1	1.3
Switzerland	0.7	0.8
Austria	1.7	1.8
Belgium	0.3	0.6
Australia	0.1	0.1
Total 9 countries	100	100

100% = overall consumption of acetylic salicylic acid (ASA) among nine countries

The online version of the original article can be found under doi:[10.1007/s10194-008-0046-6](https://doi.org/10.1007/s10194-008-0046-6).

H.-C. Diener (✉)  
Department of Neurology,  
University Duisburg-Essen, Essen, Germany  
e-mail: [hans.diener@uni-duisburg-essen.de](mailto:hans.diener@uni-duisburg-essen.de)

R. Schneider · B. Aicher  
Boehringer Ingelheim Pharma GmbH & Co. KG,  
Ingelheim, Germany